
- ONCOLOGY Vol 23 No 8
- Volume 23
- Issue 8
Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors
Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors
Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors. Study findings demonstrated that median progression-free survival was 11.1 months in patients treated with sunitinib compared to 5.5 months in patients treated with placebo. Researchers presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
The independent Data Monitoring Committee recommended halting the trial earlier this year because sunitinib showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing.
Articles in this issue
about 17 years ago
Resolving Confusion: The New Realities of Mantle Cell Lymphomaabout 17 years ago
Reishi Mushroomabout 17 years ago
Unraveling the Mystery of a Supraclavicular Massabout 17 years ago
Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challengeabout 17 years ago
US Oncology Launches Oncology-Specific EHRabout 17 years ago
Effective Local Therapy and Long-Term Survival in Breast Cancerabout 17 years ago
Local Therapy Matters






















































